Medical device firm Retractable's Q3 sales dip

Reuters
11/15
Medical device firm Retractable's Q3 sales dip

Overview

  • Retractable Technologies Q3 2025 sales slightly declined to $10.1 mln from $10.3 mln last year

  • Operating loss for Q3 2025 reduced to $3.7 mln from $5.1 mln last year

  • Company reports Q3 net income of $371 thousand, aided by $2.4 mln unrealized gains

Outlook

  • Tariffs expected to continue impacting costs in future periods

  • Uncertainty remains regarding timing of future international orders

Result Drivers

  • TARIFF IMPACT - Co says tariffs continue to materially affect costs, spending $2.3 mln on tariffs in first nine months of 2025

  • PRODUCT MIX - Higher domestic selling prices due to shift in product mix, with decreased EasyPoint needle sales

  • INTERNATIONAL SALES - International revenues increased 25% in Q3, but average selling price declined due to product discounts

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

$10.10 mln

Q3 Operating Income

-$3.70 mln

Press Release: ID:nBw2MxtN9a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10